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Abstract
Background
When sentinel node dissection reveals breast cancer metastasis, completion
axillary lymph node dissection is ideally performed during the same operation.
Intraoperative histologic techniques have low and variable sensitivity. A new
intraoperative molecular assay (GeneSearch BLN Assay; Veridex, LLC, Warren,
NJ) was evaluated to determine its efficiency in identifying significant sentinel
lymph node metastases (>.2 mm).
Methods
Positive or negative BLN Assay results generated from fresh 2-mm node slabs
were compared with results from conventional histologic evaluation of adjacent
fixed tissue slabs.
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Results
In a prospective study of 416 patients at 11 clinical sites, the assay detected 98%
of metastases >2 mm and 88% of metastasis greater >.2 mm, results superior to
frozen section. Micrometastases were less frequently detected (57%) and assay
positive results in nodes found negative by histology were rare (4%).
Conclusions
The BLN Assay is properly calibrated for use as a stand alone intraoperative
molecular test.
Keywords
Breast cancer, Molecular, Gene, Diagnostic, Auxiliary
________________________
For breast cancer patients, the status of the axillary sentinel lymph node(s) (SLN)
provides important staging information and usually determines whether formal
axillary lymph node dissection will be performed. If axillary node dissection is
needed, it is ideally performed immediately after SLN dissection during the same
operation. Current, widely practiced, intraoperative methods for detecting SLN
metastases include frozen section and touch preparation (imprint cytology). Both
of these approaches have limited sensitivity with wide performance variability
compared with postoperative permanent section histology. When compared with
final permanent pathology results, the reported sensitivity of frozen section SLN
analysis varies from 58% to 87% [1]. Touch preparation has similar limitations in
sensitivity [2]. A positive intraoperative SLN finding spares the patient a later
return to surgery for completion axillary dissection. However, substantial falsenegative findings with current histologic intraoperative methods cause patients
and their families significant distress when they are told later that the test was
incorrect. Not only must the patient and her family go through a second
operation, but they also have to cope with the news that the prognosis is worse
and the required treatment more extensive than they had believed. In addition,
the second surgery after a false-negative frozen section incurs additional costs
and potential additional anesthetic and operative morbidity.
Accurate intraoperative molecular analysis of all or part of the SLN offers the
potential to significantly reduce false-negative findings that necessarily occur with
the limited tissue sampling of conventional histologic methods [3], [4], [5], [6] and
[7]. Although a molecular assay can overcome the errors resulting from limited
tissue sampling associated with traditional histologic evaluation, several new
challenges arise. First, unless calibrated appropriately, molecular assays may
detect clinically insignificant amounts of metastatic cellular material. Presently,
nodal breast cancer metastatic deposits <.2 mm are classified as node negative
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(N-0) [8], with minimal or unknown clinical importance. A molecular breast SLN
assay must be calibrated to routinely indicate a positive result only with quantities
of disease ≥.2 mm to spare patients from axillary dissections or adjuvant
chemotherapy, which would be considered unwarranted by current standards.
Second, the molecular assay must be validated in an independent dataset to
confirm proper calibration.
The validation of a molecular SLN assay with accuracy superior to conventional
sampling-based histology presents an even more challenging problem. Because
of the likelihood that an accurate molecular assay will be more thorough than
conventional histology, the assay will likely detect disease missed by the
reference histologic test to which it is compared. Traditional test validation
methodology would misleadingly term such a finding “false-positive.” Therefore, a
modified approach is needed.
We evaluated a novel, intraoperative reverse transcriptase-polymerase chain
reaction assay for SLN breast cancer metastasis (GeneSearch BLN Assay;
Veridex, LLC, Warren, NJ) in a prospective, multisite trial. The molecular test was
calibrated in vitro so that positive findings were only associated with significant
levels of the targeted messenger RNA transcripts [9]. We have presented a
comprehensive, classic sensitivity and specificity evaluation of this new test
elsewhere [10]. In the current analysis, we hypothesized that agreement between
the molecular test on one part of the SLN and conventional pathology from
another part (alternating slices) would be greatest when metastatic involvement
was most extensive, as would be expected with histologic evaluation of
alternating tissue sections of the same node. We also examined assay
performance related to breast tumor type and stage and compared assay
performance with the performance of current intraoperative tests. In particular,
we investigated if the assay could be particularly beneficial for difficult-to-detect
metastases, such as those seen in stage I cancer or lobular cancer. Lobular
metastases are particularly challenging for conventional, sampling-based
histologic methods because they are often distributed as diminutive clusters or
single cells. There is growing consensus that such metastatic deposits should be
counted as node positive, even when none is >.2 mm, when a substantial
amount of the node is so involved [11].
Methods
The calibration and validation of the molecular BLN Assay required 2 separate
trials: (1) a beta (cutoff) trial of 304 patients to establish a threshold between
insignificant and significant levels (corresponding with histologic metastatic
deposits >.2 mm) of the markers mammaglobin and cytokeratin 19 (CK19) and
(2) a pivotal (validation) trial of 416 patients for independent performance
verification compared with permanent-section hematoxylin and eosin and
immunohistochemical evaluation. Both trials were completed between July 2004
and December 2005 (Pre-IDE I040002). Patients at least 18 years of age with a
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diagnosis of invasive adenocarcinoma of the breast and scheduled for a SLN
dissection were eligible for the calibration or validation study. Patients were
excluded if they were participating in other research studies that would prevent
their full study participation, if they had a prior axillary surgery on the same body
side as the scheduled SLN dissection, if proper informed consent signature was
not obtained, or if they did not meet inclusion criteria listed earlier. All patients in
the final data analysis had written informed consent, and the study protocols
were reviewed and approved by the appropriate ethics review board at each site.
Twelve clinical sites in the United States were selected based on clinical trial
performance history and previous research experience with SLN studies through
the American College of Surgeon’s Oncology Group or The National Surgical
Adjuvant Bowel and Breast Project. Site technicians were trained and qualified
with the BLN Assay technology.
Node processing and comparison of BLN Assay findings with conventional
histology
SLNs were identified intraoperatively and dissected according to the standard
procedures of each site. Nodes were transported to the pathology testing area
within 15 minutes. All nodes designated as sentinel nodes (including “grossly
positive” nodes) were analyzed, except at the site pathologist’s discretion (ie,
node too small for adequate histological assessment for patient care if shared for
molecular assay) or because of protocol deviation. Each node was sectioned
along the short axis into an even number of slabs (1.5–3.0 mm thick). Alternate
slabs were prepared for histologic evaluation or the BLN Assay. Histologic
evaluation of each lymph node complied with or exceeded current College of
American Pathologists’ recommendations. The BLN Assay procedure using
reverse-transcriptase polymerase chain reaction includes liquefaction of the
selected tissue, allowing comprehensive analysis of all cellular material in the
tissue sample, thus eliminating sampling error. Unfortunately, the same tissue
slab cannot be examined by both the BLN assay, which uses fresh tissue, and
conventional histology, which uses formalin-fixed tissue. This makes direct
comparison between the 2 methods on the exact same tissue impossible.
Comparison of findings from adjacent tissue slabs is required. Perfect
concordance between adjacent tissues cannot be expected because small
metastases may be singular or spaced several millimeters apart. However, if
both tests accurately detect metastatic disease, increasing the number or size of
the metastatic cellular colonies will be associated with an increasing
concordance of findings in adjacent tissue slabs.
Site slides and histologic intraoperative tests
The tissue slabs reserved for histologic analysis were processed for permanentsection hematoxylin and eosin, according to the standard operating procedures
of each site (site slides). The site also analyzed intraoperative frozen section or
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touch preparation slides taken from these same slabs according to their standard
methods. Patient management was based solely on histologic analysis. Site
personnel and patients were blinded to results from the BLN Assay.
Central slides
Additional histologic sections (central slides), adjacent to but separate from the
sections prepared as Site Slides were taken, processed for permanent-section
hematoxylin and eosin, and sent to a central pathology site for evaluation. Tissue
was sectioned for central slides according to the study protocol; three 4- to 6-µm
thick sections were collected at 3 levels, approximately 150 µm (.15 mm) apart.
(Note: this would detect a .2-mm metastasis in a 1.5-mm slab in one third of
cases or in a 3.0-mm slab in one sixth of cases, exceeding current College of
American Pathologists’ recommendations). When no metastasis was observable
with hematoxylin and eosin staining, adjacent sections were also stained for
immunohistochemical analysis, either on-site or by an outside laboratory (Albany
Medical College, Department of Pathology, Albany, NY) and evaluated by the
site pathologist or sent to the central laboratory for evaluation.
Histologic evaluation
Hematoxylin and eosin site slides and any site immunohistochemistry slides were
examined by the site pathologist for evidence of metastases. All positive
histologic findings (hematoxylin and eosin or immunohistochemical) on site slides
were reviewed by central pathologists.
Each hematoxylin and eosin central slide was independently evaluated at the
central pathology laboratory by 2 pathologists and a third pathologist in cases of
disagreement. Only nodes with central review slide hematoxylin and eosin results
were included in the study. A patient was considered positive if 2 independent
pathologists evaluated the same histologic sections (either hematoxylin and
eosin or immunohistochemistry slides) as containing metastasis >.2 mm. Central
versus site slide results analysis permitted estimation of the amplitude of
sampling error associated with conventional histologic evaluation (see Results).
The overall histology result (OHR) was determined for each patient. When either
the final central slides and/or final site slides (confirmed by central review) result
was positive, the OHR for the node was designated positive. If either the site
slide and/or any immunohistochemical results were not available, the central
slide result alone was used as the OHR for the node.
GeneSearch BLN Assay results
All GeneSearch BLN Assay results were provided to Veridex for analysis (and
blinded to site personnel). To provide a positive or negative assay sample result,
the quantitative expression data were applied against specific mammaglobin and
CK19 cutoff values based on data from the calibration (cutoff) study. The cutoff
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values were selected to correspond to histologically identified metastases >.2
mm in adjacent tissue slabs in 95% of cases. The cutoff values determined in the
cutoff study (n = 304 patients) were then applied to the validation data set
consisting of results from 416 independent patients. The assay result for a
patient was considered positive if any node from the patient tested positive. If all
nodes from a patient tested negative, then the assay result for the patient was
considered negative. If the sample result from any node from a patient was
invalid and all other node sample results were also invalid or negative, then the
assay result for that patient was considered invalid.
Analysis
The primary endpoint was the overall agreement between the BLN Assay and
the OHR for a given patient indexed to the size of metastatic deposits detected
by histology and related to lobular versus other histology in the primary tumor.
Secondary endpoints included (1) agreement of the BLN Assay with the OHR
versus that of intraoperative frozen section and touch preparation and (2) a
comparison of site slide versus central slide findings to provide a sampling error
estimate for histological analysis. Eligible patients with invalid BLN Assay results
were considered assay negative for performance calculations and were included
in the analyses because, in clinical use, invalid results would not provide
conclusive evidence of metastases and would provide the surgeon with no
information on which to base clinical decisions. Invalid results can arise from
inappropriate sampling (eg, all fatty tissue or no nodal tissue), operator error, or
equipment malfunction. Bayesian statistical study design and analysis were
performed and provided by Berry Consultants (Don Berry, Ph.D, and Scott Berry,
Ph.D., Houston, TX). Statistical analyses, SAS programming, and validation were
performed by Veridex.
Results
Experienced technicians performed the assay on 1 to 3 nodes in about 30 to 35
minutes compared with about 35 to 55 minutes for those with less practice.
Assay performance was very similar in the validation and cutoff studies. Data are
reported here for the validation study, except when the sample sizes are small;
then the data are shown for both studies separately and combined. All analyses
were performed on a “per-patient” basis. The intraoperative BLN Assay detected
disease in 98% (95% confidence interval, 93%–100%) of cases when
histologically confirmed metastases >2 mm were found in adjacent tissue slabs
(n = 94). The assay was positive in 57% (95% confidence interval, 35%–77%) of
patients when micrometastatic disease .2 to 2 mm was detected in the adjacent
slabs (n = 23). Overall, the assay reported metastasis 88% of the time when
metastatic disease ≥.2 mm was detected histologically in adjacent tissue slabs.
When metastases <.2 mm were found on histologic sampling of the adjacent
tissue slabs (small clusters or isolated tumor cells), the assay was positive in 5 of
20 patients. The assay was positive in 12 of 275 (4%) patients with no
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histologically detected cancer in adjacent tissue slabs. Table 1 shows the
summary of BLN Assay results and OHR agreement.
Assay performance was similar across different stages of disease and across
various tumor types (Table 2). The assay reported disease in approximately 80%
of patients when lobular metastases (particularly difficult to identify by histology
[4]) were present in adjacent tissue slabs. Table 3 shows the assay performance
in lobular cancer patients in the validation study, cutoff study, and both studies
combined when compared with OHR (permanent section histology).
Table 4 shows in the same patients the BLN Assay performance versus the
performance of histologic intraoperative tests. Not all clinical sites used histologic
intraoperative tests. All tests are compared with OHR. The assay detected about
10% more metastases than did frozen section (86 assay positive versus 77
frozen section positive of 90 OHR positive) and nearly 30% more than did touch
preparation (7 assay positive versus 5 touch prep positive of 11 OHR positive).
Early-stage disease and lobular cancers can be difficult cases in which to
accurately detect metastases. Table 5 shows the performance of the BLN Assay
versus that of frozen section in early-stage disease and in patients with lobular
cancer. Data are shown for the validation study, cutoff study, and for both studies
combined. The assay identifies metastatic disease in approximately 10% more
patients with stage I disease and 25% more patients with lobular cancer than
does frozen section (compared with total OHR positive).
Permanent section histologic evaluations are reported to miss at least 10% to
15% of metastases >.2 mm because of practical limitations in sampling [7] and
[12]. The same sampling errors necessarily contribute to the lack of perfect
agreement between the BLN Assay and the OHR. This sampling error would be
expected to be most apparent when metastases are small and infrequent, as with
micrometastases. Figure 1 shows that the assay agreement with positive OHR
found on adjacent ~2-mm node slabs is best when the metastases are larger and
likely to be distributed across the assay and histology node pieces (the P value of
Cochran-Armitage test for trend is <.001).
There are fewer cases of BLN Assay–positive/histology-negative results when
histologic sampling accuracy is increased. Thus, assay positivity is better
matched by histology when more extensive sampling is used for the histologic
evaluation (central and site slides combined) because this reduces the number of
metastases being missed by histology (Table 6).
Sampling errors in histology testing are apparent when comparing histologic
evaluations on the 2 sets of histologic slides: site slides versus central slides.
These are nearby sections from the same ~2-mm node slabs, yet significant
disagreements are seen where 1 set of slides contain metastatic tissue and the
other set does not (Table 7, Table 8 and Table 9). The lack of perfect agreement
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is caused by the analysis of different section samples from the same lymph node
because significant metastases can be missed in nearby tissue left uncut on the
block [13] and [14]. If site slide findings are compared with central slide findings
as the reference, the agreement of the 2 histologic evaluations approximates the
agreement between the BLN Assay and OHR on different ~2-mm node slabs.
These data confirm that the lack of perfect agreement between OHR and the
BLN Assay is primarily caused by the evaluation of different parts of the node.

Comments
The currently recommended protocol for SLN processing (according to the
College of American Pathologists, 5 µm from 3 levels of each 2- to 3-mm
fragment of the node [15]), guarantees evaluation of <1% of the volume of the
selected tissue [16]. Comprehensive histologic examination of a 1.5-cm lymph
node aimed at finding any metastasis ≥.2 mm would require 75 sections, which is
unobtainable in common practice. This limitation in the current standard of care
makes it challenging to evaluate newer tests that are able to sample more tissue
and are likely to be more sensitive than the “gold standard” reference test. The
current study evaluated a new molecular test against a permanent section
histologic protocol that was more thorough than is usually performed and used a
central review of histologic slides to reduce evaluation errors. The study also
evaluated histologic results on 2 sets of tissue sections taken from nearby
regions of the same node. By comparing site slide findings to central slide
findings, an estimate of sampling errors (differences caused by testing of
different tissue from the same node) can be made. Because the BLN Assay
produces a result by testing fresh homogenized tissue, the same tissue cannot
be tested by both the assay and permanent section histology, which requires
fixed tissue. This sampling difference will necessarily lead to disagreements
between the assay and histology, especially when metastases are smaller and
less widely distributed in the node.
The BLN Assay is a molecular test that can test 50% or more of the node in time
to permit intraoperative evaluation. In a prospective study of 416 patients, with
fresh nodal tissue tested by 11 clinical sites, the assay yielded efficient
intraoperative detection of clinically important sentinel node metastasis, which
will allow the surgeon and the patient to avoid a second operation for completion
axillary dissection in 98% of patients if the policy is to return for metastases >2
mm or 88% if the policy is to return for any metastasis >.2 mm. Micrometastases
(from .2 to 2.0 mm) were less frequently detected (57%) and assay-negative
results in nodes found positive by histology were rare (4%).
The disagreements seen between permanent section histology performed on
adjacent-node slabs and the BLN Assay results were very similar to the
disagreements seen between histology preformed on site slides versus central
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slides. These data indicate that when the assay and histology disagree, both
tests are likely to be correct for the tissue portions each is evaluating.
Discrepancies between evaluations on different node tissue (whether assay
versus histology or histology versus histology) are greatest when metastases are
small because they are poorly distributed in the node tissue. These findings
support the need for tests that can efficiently evaluate more of the node for
clinically significant metastases because breast cancer is found earlier and
earlier and metastases will more likely be smaller.
As reported previously [17], in cases for which the BLN Assay result and the
OHR were different, residual node homogenate or RNA extract from the assay
testing was evaluated with other molecular markers for nodal metastases
including B305D, B726, prolactin inducible protein, and prostate-derived Ets
transcription factor [18], [19] and [20]. This testing was performed to confirm the
BLN Assay results on the same tissue. These independent molecular test results
confirmed as positive 76% of the BLN Assay–positive/OHR-negative nodes and
confirmed as negative 100% of the BLN Assay–negative/OHR-positive nodes.
These findings again suggest that when the BLN Assay and OHR are in
disagreement, both are correct for the nodal portions each is evaluating.
Four percent of patients (17/416) had BLN Assay–positive results with no
metastasis detected by conventional histology in adjacent tissue slabs. Could the
assay produce real false-positive findings and lead to unnecessary axillary
dissections? For reasons supported by our findings, we conclude that the BLNpositive/OHR-negative cases represent misses of metastatic disease by
conventional histology. Histologic assessment of study sections taken
immediately adjacent to standard site sections used for patient care shows the
same study negative/standard-section positive rate. Study and standard site
slides were all reviewed by the same pathologists. The assay is calibrated in in
vitro studies to require approximately 2,000 cells to yield a positive result.
External controls act as a further safety net against truly false-positive results.
Recalibrating the assay cutoff to ignore or miss significant disease, at precisely
the rate it is missed by conventional histology, would necessarily lead to lower
sensitivity for the detection of clinically significant disease.
More detailed evaluation of the BLN Assay results indicates that the assay may
be particularly helpful for difficult-to-detect early-stage breast cancer metastases
or metastases from lobular cancer. Compared with current histologic frozen
section intraoperative testing, the BLN Assay showed improved sensitivity
ranging from approximately 10% to 30%. Another advantage of the BLN Assay
over frozen sectioning is that more tissue can be evaluated efficiently and there
is no freezing artifact on the portions of node undergoing permanent section
histology.
In summary, these data support the use of the BLN Assay as a properly
calibrated intraoperative molecular test that can reduce the need for second
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surgeries to complete the axillary dissection on SLN-positive patients. In addition,
the assay has value in augmenting permanent section histologic results to obtain
better certainty of a correct node diagnosis by evaluating more of the tissue. The
pathologist, surgeon, and patient can be more certain a negative node diagnosis
is accurate when both the BLN Assay result on half of the node and standard
histology on the other half are negative.
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TABLES & FIGURES

Table 1.
Summary of BLN Assay results and OHR agreement
Assay−/OHR−

Assay+/OHR+

Assay+/OHR−

Assay−/OHR+

N

278 (67%)

106 (25%)

17 (4%)

15 (4%)

416

% Agreement
92.3

For OHR, + is metastases >.2 mm and − is metastases ≤.2 or no detectable metastases.

Table 2.
Assay performance by stage and type of breast cancer
Tumor
stage/type

N

Assay−/OHR−

Assay+/OHR+

Assay+/OHR−

Assay−/OHR+

%
Agreement

Stage I

247

202 (82%)

29 (12%)

10 (4%)

6 (2%)

93.5

Stage II

125

54 (43%)

55 (44%)

7 (6%)

9 (7%)

87.2

Stage III

20

8 (40%)

12 (60%)

0 (0%)

0 (0%)

100

Invasive
ductal

335

223 (67%)

87 (26%)

14 (4%)

11 (3%)

92.5

Invasive
lobular

57

34 (60%)

16 (28%)

3 (5%)

4 (7%)

87.7

Invasive
other

23

20 (87%)

3 (13%)

0 (0%)

0 (0%)

100

Table 3.
BLN assay results and OHR agreement in patients with lobular cancer
Study

N

Assay−/OHR−

Assay+/OHR+

Assay+/OHR−

Assay−/OHR+

%
Agreement

Validation

57

34 (60%)

16 (28%)

3 (5%)

4 (7%)

87.7

Cutoff

40

26 (65%)

10 (25%)

1 (3%)

3 (8%)

90.0
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Study

N

Assay−/OHR−

Assay+/OHR+

Assay+/OHR−

Assay−/OHR+

%
Agreement

Combined

97

60 (62%)

26 (27%)

4 (4%)

7 (7%)

88.7

Table 4.
Assay versus other intraoperative test performance
N

Test method

Test−/OHR−

Test+/OHR+

Test+/OHR−

Test−/OHR+

%
Agreement

319

Frozen
Section

224 (70%)

77 (24%)

5 (2%)

13 (4%)

94.4

Assay

216 (68%)

86 (27%)

13 (4%)

4 (1%)

94.7

Touch Prep

18 (62%)

5 (17%)

0 (0%)

6 (21%)

79.3

Assay

18 (62%)

7 (24%)

0 (0%)

4 (14%)

86.2

29
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Table 5.
Assay and frozen section performance in stage I and lobular cancer patients
Study

N

Test method

Test−/OHR−

Test+/OHR+

Test+/OHR−

Test−/OHR+

% Agreement

187

Frozen

158 (84%)

22 (12%)

3 (2%)

4 (2%)

96.3

Assay

155 (83%)

25 (13%)

6 (3%)

1 (1%)

96.3

Frozen

30 (67%)

9 (20%)

1 (2%)

5 (11%)

86.6

Assay

29 (64%)

14 (31%)

2 (4%)

0 (0%)

95.6

Frozen

82 (82%)

11 (11%)

1 (1%)

6 (6%)

93.0

Assay

77 (77%)

12 (12%)

6 (6%)

5 (5%)

89.0

Frozen

15 (63%)

6 (25%)

0 (0%)

3 (12%)

87.5

Assay

15 (63%)

7 (29%)

0 (0%)

2 (8%)

91.7

Frozen

240 (84%)

33 (11%)

4 (1%)

10 (4%)

95.1

Assay

232 (81%)

37 (13%)

12 (4%)

6 (2%)

93.7

Frozen

45 (65%)

15 (22%)

1 (1%)

8 (12%)

86.9

Assay

44 (64%)

21(30%)

2 (3%)

2 (3%)

94.2

Validation study
Stage I

Lobular

45

Cutoff study
Stage I

Lobular

100

24

Combined studies
Stage I

Lobular

287

69
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Table 6.
Assay performance by extent of histologic analysis
Reference
histology

N

BLN−/Hist−

BLN+/Hist+

BLN+/Hist−

BLN−/Hist+

%
Agreement

Central slides
only

407

278 (68%)

91 (22%)

27 (7%)

11 (3%)

90.7

Site slides only

407

275 (68%)

95 (23%)

23 (6%)

14 (3%)

90.9

Central & site
slides

407

275 (68%)

101 (25%)

17 (4%)

14 (3%)

92.4

Table 7.
Agreement between site slide results and central slide results
Site slides

Central slides
>2 mm

.2–2 mm

<.2 mm

None detected

Total

>2 mm

79

3

0

4

86

.2–2 mm

5

9

0

9

23

<0.2 mm

0

2

0

4

6

None detected

3

1

1

288

293

Total

87

15

1

305

408

Table 8.
Summary of site slides and central slides agreement
Site−/central−

Site+/central+

Site+/central−

Site−/central+

N

% Agreement

293 (72%)

95 (23%)

13 (3%)

6 (2%)

408

95

+ is metastases >.2 mm and − is metastases ≤.2 or no detectable metastases.

_______________________
Authors’ version prior to publication. The published version is available at
http://dx.doi.org/10.1016/j.amjsurg.2007.07.008, copyright © 2007 by Excerpta Medica Inc.

Table 9.
Site slides and central slides agreement for patients with detectable nodal tumor
cells
Site and/or central

N

Site+/central+

Site+/central−

Site−/central+

Total disagree

>2 mm

94

87 (93%)

4

3

7 (7%)

.2–2

29

17 (59%)

9

3

12 (41%)

<0.2

7

2 (29%)

4

1

5 (71%)

Fig. 1.
BLN assay positivity by the size of metastases in the adjacent tissue.
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